C-erbB-2, p53, N-ras expression in hepatocellular carcinoma
Tóm tắt
To assess the relationship between C-erbB-2, p53, N-ras status at a premalignant stage and in HCC, the authors studied the imunohistological expression of these genes in HCC, liver cirrhosis and in the adjacent normal resected liver tissue, using monoclonal antibody to mutated p53 and activated C-erbB-2, N-ras. C-erbB-2 was expressed in 97.1% (35/36) of HCC and 100% (18/18) of hepatic cirrhosis, low level C-erbB-2 expression was observed in 2/14 (14.3%) of normal liver specimens; The positive incidence of overexpression of mutant p53 protein in HCC and hepatic cirrhosis were 55.6% (20/36) and 66.7% (10/18) respectively; 29 (76.5%) specimens of HCC and 16 (88.9%) of hepatic cirrhosis were positive for N-ras protein. The overexpression of the three oncogene proteins were significantly higher than that of normal liver tissues (P<0.01). These results indicated that activated C-erbB-2, N-ras and altered p53 genes may have a role in human HCC pathogenesis through promiting the development of HCC from hepatic cirrhosis and the progression of HCC.
Tài liệu tham khảo
Shin C, Padhylc MM, Weinberg RA. Transforming genes of carcinomas and neuroblastoma introduced into mouse fibroblasts. Nature 1981; 290: 261.
Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erbB-related gene encoding a 185,000-M tumor antigene. Nature 1984; 312: 513.
Sembak, Kamata N, Toyoshima K, et al. A verb related protooncogene, C-erbB-2, is distinct from C-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985; 82: 6497.
Martha QL, Lynn CH, Gary LK, et al. C-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer 1995; 75 (12): 2891.
Enriqueta F, Josep M, Del C, et al. Overexpression of C-erbB-2 in epithlial ovarian cancer. Cancer 1995; 75 (8): 2147.
Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644.
Perry ME, Levine AJ. Tumor suppressor p53 and the cell cycle. Curr Opinion Genet Development 1993; 3: 50.
Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523.
Nigro JM, Baker SJ, Presinger CA, et al. Mutation in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705.
Eccles DM, Brett L, Lessells A, et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992; 65: 40.
Nelly L, Ahamed E, Eithan G, et al. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995; 75 (10): 2420.
Helmut EG, Wolffram M, Gerhard H, et al. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinomas. Cancer 1995; 76 (5): 720.
Porter PL, Gown AM, Karamp SG, et al. Wildspread p53 overexpression in human malignant tumors. Am J Pathol 1992; 140: 145.
Chang F, Syrjanens, Tervahant A, et al. Tumor-genesis associated with the p53 tumor suppressor gene. Br J Cancer 1993; 68: 653.
Harris CC, Hollstern M. Clinical implication of the p53 tumor suppressor gene. N Engl J Med 1993; 329: 1318.
Barbacicl M. Ras gene. Annal Rev Biochem 1987; 56: 779.
McGrath JP, Nozawa YS, Lucy WK, et al. Structure and organization of the human Ki-ras protooncogene and a related processed psceudogene. Nature 1985; 304: 501.
Bos JL, Nacy KS, Muine ZL, et al. Ras oncogene in human cancer. Cancer Res 1989; 49: 4682.
Bos JL, Nacy KS, Caro JS, et al. The ras family and human carcinogenesis. Mutat Res 1988; 195: 255.
Michihiro F, Hirotoshi Dosaka-Akita, Yoshikazu K, et al. Prognostic significance of p53, p21 expression in nonsmall cell lung cancer. Cancer 1995; 76: 2457.
J Michael Bioshop. The molecular genetics of cancer. Science 1987; 235: 305.
Hupp TR, Meek EW, Midgley CA, et al. Regulation of the specific DNA binding function of p53. Cell 1992; 70: 923.
Livingstone LR, White A, Sprouse J, et al. Altered cell cycle arrest and gene amplication potential accompany loss of wild-type p53. Cell 1992; 70: 923.
Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian carcinoma. J Clin Oncol 1994; 12: 64.
Chang F, Syrjanen S, Syrjanen K, et al. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993; 88: 174.
Brambilla E, Gazzeris, Jacrot M, et al. Immuno-histochemical study of p53 in human lung carcinoma. Am J Pathol 1993; 143: 199.
Kacinski BM, Mayer AG, King BL, et al. Neu protein overexpression benign, borderline, and malignant ovarian neoplasms. Gyneocol Oncol 1992; 44: 245.
Jiang W, Steveb J, Maurren K, et al. Rapid detection of ras oncogene in human tumors: application of colon, esophogeal and gastric cancer with sequence specific oligo-nucleotides. Oncogene 1989; 4: 823.
Hsia CC, Kleine DE, Axiotis CA, et al. Mutation of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J Natl Cancer Inst 1992; 84: 1638.
Slagle BL, Zhou YZ, Butel JS, et al. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinoma. Cancer Res 1991; 51: 49.